Semaglutide Shows Promise in Reducing Alcohol Consumption in Adults with Alcohol Use Disorder: A Randomized, Placebo-Controlled Trial

A recent study published in JAMA Psychiatry indicates that semaglutide, a GLP-1 drug, may reduce alcohol consumption in adults with alcohol use disorder. The phase 2 randomized, placebo-controlled trial involved 48 participants and assessed various outcomes related to alcohol misuse. Participants were given weekly injections of either low-dose semaglutide or a placebo over nine weeks, and their alcohol consumption was monitored. Results showed that the semaglutide group drank significantly less alcohol in laboratory sessions compared to the placebo group. While the frequency of drinking remained similar between the groups, the semaglutide group consumed less alcohol on days when they did drink. The study suggests a causal effect of semaglutide on reducing the amount of alcohol consumed. However, the study involved participants not seeking treatment and with a BMI of at least 23, and mostly 30 or higher. Further research is needed to evaluate the effects of semaglutide on individuals seeking treatment, those with lower BMIs, and over longer periods.